Literature DB >> 35531367

Identification of Risk Factors for Coexisting Sinusitis and Inflammatory Bowel Disease.

Victoria Rai1, Cindy Traboulsi1, Alexa Silfen1, Max T Ackerman1, Amarachi I Erondu1, Jordan E Karpin1, George Gulotta1, David T Rubin1.   

Abstract

BACKGROUND: This study aimed to analyze the association of coexisting sinusitis and IBD, establish significant factors involved in their development, and enable further biological correlation between these two diseases.
METHODS: The IBD and Sinusitis Study at UChicago Medicine (TISSUe) is a retrospective, single-center study. We reviewed patients to confirm IBD and chronic sinusitis diagnoses. Case-control propensity score matching was performed using matched controls with IBD only or sinusitis only. Statistical methods included Chi-squared test and Wilcoxon rank sum test. Logistic regression analysis was performed, and factors were considered significant if p<0.05.
RESULTS: Stratifying 214 patients with coexisting IBD and sinusitis, 176 patients had IBD first and 38 patients had sinusitis first. Multivariable analysis of factors associated with subsequent disease with matched controls determined that duration of disease, UC, steroid exposure ever, and younger age of IBD diagnosis were associated with subsequent sinusitis in patients with IBD; steroid exposure ever and duration of sinusitis were significantly associated with subsequent IBD in patients with sinusitis.
CONCLUSIONS: This study suggests that IBD maintenance therapies are not associated with increased risk of sinusitis, as proposed by adverse events in clinical trial data; rather, UC diagnosis and duration of disease may be more influential in sinusitis development. While further studies are necessary, this study also demonstrates that sinusitis precedes IBD in some patients, probing its biological association with IBD and possible classification as an extraintestinal manifestation.

Entities:  

Keywords:  co-morbidities; inflammatory bowel disease; management; multi-disciplinary care; sinusitis

Year:  2021        PMID: 35531367      PMCID: PMC9075692          DOI: 10.1093/crocol/otab054

Source DB:  PubMed          Journal:  Crohns Colitis 360        ISSN: 2631-827X


  35 in total

Review 1.  Impact of tobacco smoke on chronic rhinosinusitis: a review of the literature.

Authors:  Douglas D Reh; Thomas S Higgins; Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2012-06-13       Impact factor: 3.858

2.  Clinical practice guideline (update): adult sinusitis.

Authors:  Richard M Rosenfeld; Jay F Piccirillo; Sujana S Chandrasekhar; Itzhak Brook; Kaparaboyna Ashok Kumar; Maggie Kramper; Richard R Orlandi; James N Palmer; Zara M Patel; Anju Peters; Sandra A Walsh; Maureen D Corrigan
Journal:  Otolaryngol Head Neck Surg       Date:  2015-04       Impact factor: 3.497

3.  Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries.

Authors:  Shailja C Shah; Hamed Khalili; Corinne Gower-Rousseau; Ola Olen; Eric I Benchimol; Elsebeth Lynge; Kári R Nielsen; Paul Brassard; Maria Vutcovici; Alain Bitton; Charles N Bernstein; Desmond Leddin; Hala Tamim; Tryggvi Stefansson; Edward V Loftus; Bjørn Moum; Whitney Tang; Siew C Ng; Richard Gearry; Brankica Sincic; Sally Bell; Bruce E Sands; Peter L Lakatos; Zsuzsanna Végh; Claudia Ott; Gilaad G Kaplan; Johan Burisch; Jean-Frederic Colombel
Journal:  Gastroenterology       Date:  2018-06-27       Impact factor: 22.682

Review 4.  Chronic Rhinosinusitis and the Evolving Understanding of Microbial Ecology in Chronic Inflammatory Mucosal Disease.

Authors:  Michael Hoggard; Brett Wagner Mackenzie; Ravi Jain; Michael W Taylor; Kristi Biswas; Richard G Douglas
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

5.  Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.

Authors:  Britt Christensen; Ruben J Colman; Dejan Micic; Peter R Gibson; Sarah R Goeppinger; Andres Yarur; Christopher R Weber; Russell D Cohen; David T Rubin
Journal:  Inflamm Bowel Dis       Date:  2018-03-19       Impact factor: 5.325

6.  Safety of infliximab in Crohn's disease: a large single-center experience.

Authors:  H Hamzaoglu; J Cooper; M Alsahli; K R Falchuk; M A Peppercorn; R J Farrell
Journal:  Inflamm Bowel Dis       Date:  2010-12       Impact factor: 5.325

7.  Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome.

Authors:  Hedvig E Jakobsson; Cecilia Jernberg; Anders F Andersson; Maria Sjölund-Karlsson; Janet K Jansson; Lars Engstrand
Journal:  PLoS One       Date:  2010-03-24       Impact factor: 3.240

Review 8.  Immunoglobulin deficiency in patients with chronic rhinosinusitis: Systematic review of the literature and meta-analysis.

Authors:  Adrien J-P Schwitzguébel; Peter Jandus; Jean-Silvain Lacroix; Jörg D Seebach; Thomas Harr
Journal:  J Allergy Clin Immunol       Date:  2015-08-29       Impact factor: 10.793

9.  Real-World Experience with Tofacitinib in IBD at a Tertiary Center.

Authors:  Roni Weisshof; Maya Aharoni Golan; Philip H Sossenheimer; Katia El Jurdi; Jacob E Ollech; Joel Pekow; Russel D Cohen; Atsushi Sakuraba; Sushila Dalal; David T Rubin
Journal:  Dig Dis Sci       Date:  2019-02-07       Impact factor: 3.487

Review 10.  Inflammatory bowel disease: Looking beyond the tract.

Authors:  Sana Chams; Reina Badran; Skye El Sayegh; Nour Chams; Ali Shams; Inaya Hajj Hussein
Journal:  Int J Immunopathol Pharmacol       Date:  2019 Jan-Dec       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.